EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Controlled trial of cervical cancer screening frequency among human‐papillomavirus‐vaccinated women

Mònica Ortega Llobet iD, Penelope Gray iD, Iacopo Baussano, K Miriam Elfström iD, Tiina Eriksson, Camilla Lagheden, Pekka Nieminen, Anna Söderlund-Strand, Joakim Dillner iD, Ville N Pimenoff, Matti Lehtinen iD

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70229 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Mònica Ortega Llobet und 10 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Cervical Cancer Elimination, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Papillomavirus Vaccines, Early Detection of Cancer, Papillomavirus Infections. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancerfonden, Centre for Innovative Medicine (CIMED), World Health Organization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cervical screening frequency has not been studied in vaccinees. As the major risk factor, oncogenic human papillomavirus (HPV) is declining due to vaccination. We report a trial to assess the effectiveness of cervical screening frequency among women HPV‐vaccinated as early adolescents (NCT02149030). In 2013, 5626 1992‐1995‐born women, who had received three doses of the HPV16/18 vaccine at ages 12–15 between 2007 and 2010 in a community‐randomized vaccination trial (NCT00534638), were allocated at age 22 into high‐intensity cytology‐based cervical screening by even birth date (Arm A1) or into low‐intensity cytology‐based cervical screening by odd birth date (Arm A2). One thousand three hundred thirty‐three women who received HPV16/18 vaccination at age 18 attended a safety of low intensity‐screening arm (Arm A3). Low‐intensity screening, where low‐grade cytological abnormalities were not revealed for 6 years, was compared to the standard high‐intensity screening used in Finland at the time. The prevalence of cytological and HPV findings was calculated at ages 22/25/28. The hazard ratio of histopathologically confirmed immediate cervical cancer precursors (HSIL/CIN2+) among participants was compared between low‐ and high‐intensity screening arms. The overall occurrence of CIN2+ was comparable in Arms A1, 0.70% and A2, 0.66%, with the corresponding hazard ratio at age 28 being 0.97 (95% confidence intervals, 0.50–1.88). By age 28, the occurrence of vaccine‐HPV types 16/18 was reduced up to 88% in the 12‐to‐15 compared to 18‐year‐old HPV‐vaccinated women. In conclusion, the risk of CIN2+ was similar for HPV‐vaccinated women who attended low‐intensity cervical screening compared to high‐intensity screening most likely due to the decline of oncogenic HPVs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsPapillomavirus VaccinesEarly Detection of CancerPapillomavirus InfectionsUterine Cervical DysplasiaHumansFemaleAdolescentAdultYoung AdultHuman papillomavirus 16Human papillomavirus 18VaccinationFinlandChildVaginal Smears

Stichwörter der Autor:innen

HPV‐vaccinationRCTcervical screening

Substanzen

Papillomavirus Vaccines

Autor:innen und Institutionen

  • Centre for Cervical Cancer Elimination, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
  • International Agency for Research on Cancer, Lyon, France.
  • Medical Faculty, Tampere University, Tampere, Finland.
  • Department of Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland.
  • Department of Laboratory Medicine, Clinical Microbiology, Skåne University Hospital Lund, Lund University, Lund, Sweden.
  • Research Unit of Population Health, Faculty of Medicine, Oulu University, Oulu, Finland.

ORCID-Profile: Mònica Ortega Llobet, Penelope Gray, K Miriam Elfström, Joakim Dillner, Matti Lehtinen

Förderung

  • Cancerfonden
  • Centre for Innovative Medicine (CIMED)
  • World Health Organization
  • Stockholm county research grants (ALF)
  • Horizon 2020 Framework Programme
  • Center for Innovative Medicine

Zitieren

APA

Ortega Llobet, M., Gray, P., Baussano, I., Elfström, K. M., Eriksson, T., Lagheden, C., Nieminen, P., Söderlund-Strand, A., Dillner, J., Pimenoff, V. N., & Lehtinen, M. (2026). Controlled trial of cervical cancer screening frequency among human‐papillomavirus‐vaccinated women. International Journal of Cancer. https://doi.org/10.1002/ijc.70229

Vancouver

Ortega Llobet M, Gray P, Baussano I, Elfström KM, Eriksson T, Lagheden C, et al. Controlled trial of cervical cancer screening frequency among human‐papillomavirus‐vaccinated women. International Journal of Cancer. 2026. doi:10.1002/ijc.70229

BibTeX
@article{OrtegaLlobet2026,
  author = {Ortega Llobet, Mònica and Gray, Penelope and Baussano, Iacopo and Elfström, K Miriam and Eriksson, Tiina and Lagheden, Camilla and Nieminen, Pekka and Söderlund-Strand, Anna and Dillner, Joakim and Pimenoff, Ville N and Lehtinen, Matti},
  title = {Controlled trial of cervical cancer screening frequency among human‐papillomavirus‐vaccinated women},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70229}
}
Kostenlos starten →